Nyxoah S.A. (NYXH)
NASDAQ: NYXH · IEX Real-Time Price · USD
10.10
-0.70 (-6.48%)
May 17, 2024, 4:00 PM EDT - Market closed

Company Description

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions.

The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.

Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Nyxoah S.A.
Nyxoah logo
Country Belgium
Founded 2009
IPO Date Jul 2, 2021
Industry Medical Instruments & Supplies
Sector Healthcare
Employees 146
CEO Olivier Taelman

Contact Details

Address:
Rue Edouard Belin 12
Mont-saint-guibert, C9 1435
Belgium
Phone 3210222355
Website nyxoah.com

Stock Details

Ticker Symbol NYXH
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $30.00
CIK Code 0001857190
ISIN Number BE0974358906
SIC Code 3841

Key Executives

Name Position
Robert Taub MBA Co-Founder and Chairman
Olivier Taelman Chief Executive Officer and Executive Director
Loic Moreau Chief Financial Officer
Bruno Onkelinx Chief Technology Officer
Mikaela Kirkwood Corporate Communication and Investor Relations Manager
An Moonen General Counsel
Remi Renard Vice President of Market and Market Access
Inge Vanwittenbergh Global Human Resource Director
David M. DeMartino Chief Strategy Officer
Jeyakumar Subbaroyan Chief Clinical Officer

Latest SEC Filings

Date Type Title
May 14, 2024 6-K Report of foreign issuer
Apr 15, 2024 6-K Report of foreign issuer
Mar 20, 2024 20-F Annual and transition report of foreign private issuers
Mar 19, 2024 6-K Report of foreign issuer
Mar 5, 2024 6-K Report of foreign issuer
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 17, 2024 6-K Report of foreign issuer
Jan 9, 2024 6-K Report of foreign issuer
Dec 11, 2023 6-K Report of foreign issuer